New Hope for EoE: Drug Dupilumab Shows Promise in Reversing Esophagus Damage

A new study suggests that a medication already used to treat eosinophilic esophagitis (EoE) may do more than just calm inflammation—it may actually help reverse some of the physical damage the disease causes to the esophagus. Researchers presented these findings at the annual Digestive Disease Week meeting, and they could change how doctors approach treatment for this increasingly common condition.

What the Study Found: A Closer Look at the REMODEL Trial

The REMODEL trial was a randomized, placebo-controlled study that examined how well dupilumab (sold under the brand name Dupixent) works in adults with EoE. The key focus was on something called “esophageal distensibility”—a measure of how well the esophagus can stretch and expand as food passes through.

After 24 weeks of treatment, the results were striking. Patients who took dupilumab saw their esophageal distensibility plateau diameter increase by an average of 1.28 mm from the start of the study. In contrast, those who received a placebo saw virtually no change (a decrease of 0.01 mm). The difference between the two groups was statistically significant, meaning it was unlikely to be due to chance.

When looking at percentage improvement, the dupilumab group experienced a 9.8% improvement in esophageal distensibility, compared to just a 1.4% improvement in the placebo group. Again, this difference was significant.

Understanding Eosinophilic Esophagitis and Why This Matters

Eosinophilic esophagitis is a chronic allergic condition that affects the esophagus—the tube that connects your mouth to your stomach. In people with EoE, certain foods or environmental allergens trigger an immune response that causes a type of white blood cell called eosinophils to build up in the esophagus. This leads to inflammation, which over time can cause the esophagus to become stiff, narrow, and scarred.

For patients, this translates into real-world problems. Common symptoms include difficulty swallowing (known as dysphagia), food getting stuck in the throat, chest pain, and heartburn that doesn’t respond to typical medications. In severe cases, the esophagus can become so narrow that food becomes lodged, requiring emergency medical attention.

The condition affects both children and adults, and its diagnosis has been rising sharply over the past two decades. Experts believe this is due to a combination of increased awareness and an actual increase in cases, possibly linked to environmental factors.

How Dupilumab Works: Targeting the Root Cause

Dupilumab is a monoclonal antibody—a type of lab-made protein that acts like a guided missile in the immune system. Specifically, it blocks two key signaling molecules called interleukin-4 (IL-4) and interleukin-13 (IL-13). These molecules are major drivers of the inflammation that causes eosinophils to accumulate in the esophagus and lead to tissue remodeling.

By blocking these signals, dupilumab essentially tells the immune system to calm down. The U.S. Food and Drug Administration (FDA) has already approved it for treating EoE, as well as for other conditions like asthma, eczema, and nasal polyps.

What makes the REMODEL trial particularly important is that it goes beyond just looking at inflammation. The researchers used a specialized tool called EndoFLIP (endolumenal functional lumen imaging probe) to measure the actual physical properties of the esophagus—specifically, how well it can stretch. This is a more functional measure of whether the esophagus is becoming scarred and stiff.

Expert Perspectives: What Doctors Are Saying

Dr. Evan S. Dellon, the lead researcher from the University of North Carolina School of Medicine, explained that these results suggest dupilumab may have the ability to modify the course of the disease itself. “The results from REMODEL demonstrate that there is the potential that dupilumab could modify the course of the disease as measured by increasing esophageal diameter compared to placebo,” he said. He noted that this is in addition to the drug’s already established ability to reduce signs of disease seen during endoscopy and under the microscope, and to improve symptoms.

Dr. Mark Malamood, director of benign esophagology at Temple Health Esophageal Disease Program in Philadelphia, who was not involved in the study, said that dupilumab is already considered indispensable in clinical practice for EoE. However, he emphasized what is new here: the confirmation of its effects on the fibrostenotic, or “remodeling,” aspects of the disease.

“Ongoing eosinophilic inflammation in EoE leads to persistent symptoms but also promotes development of esophageal fibrosis with subsequent luminal narrowing, reduced compliance, and eventual stricturing,” Malamood explained. Traditionally, these complications have required procedures like esophageal dilation (stretching the esophagus with a balloon or other device) along with medical therapy. This study suggests that some of these issues—specifically luminal narrowing and reduced compliance—may be treatable with medication alone.

Study Details: Who Participated and What Happened

The REMODEL trial included 69 adults from 30 medical centers across the United States, Brazil, Canada, Israel, and Switzerland. The average age of participants was 37, and about one-third were women. This relatively small sample size is one limitation of the study, as it may not fully represent the broader population of people with EoE.

At the start of the study, participants had significant disease activity. Their average esophageal distensibility plateau diameter was 17.1 mm (a healthy esophagus can typically stretch much more than this). Their average peak eosinophil count was 79.6 eosinophils per high-power field (eos/hpf)—far above the normal level of zero. Their Dysphagia Symptom Questionnaire score averaged 29.2 on a scale of 0 to 84, indicating moderate to severe difficulty swallowing.

A total of 46 participants received 300 mg of dupilumab, while 23 received a placebo. The study lasted 24 weeks.

Key Results at a Glance

The improvements went beyond just esophageal distensibility. Here are some of the other important findings:

• Esophageal distensibility: 43% of patients on dupilumab saw at least a 1 mm improvement, compared to only 13% on placebo. Even more striking, 28% of dupilumab patients had a ≥2 mm improvement and 15% had a ≥3 mm improvement—versus 0% in the placebo group for both.
• Endoscopic appearance: Using the Eosinophilic Esophagitis Endoscopic Reference Score (EREFS), which ranges from 0 to 18, the dupilumab group improved by an average of 4.89 points, while the placebo group actually worsened slightly by 0.07 points. Both inflammatory and fibrostenotic subscores showed significant improvement.
• Microscopic healing: On the Eosinophilic Esophagitis Histology Scoring System (EoEHSS), which measures tissue damage under a microscope, dupilumab patients saw significant improvements in both grade (how severe the changes are) and stage (how advanced they are).
• Histologic remission: 59% of dupilumab patients achieved a peak eosinophil count of 6 or fewer per high-power field—a standard definition of remission—compared to just 4% of placebo patients. That means dupilumab patients were 22 times more likely to achieve remission.
• Histologic response: 78% of dupilumab patients achieved a peak eosinophil count below 15 eos/hpf, compared to 4% on placebo—a 57-fold difference.

Safety and Side Effects

As with any medication, safety is a concern. In the study, treatment-emergent adverse events (TEAEs) occurred in 62% of dupilumab patients and 48% of placebo patients. The most common side effects were injection site pain and swelling, and headache. One patient in each group required rescue treatment, and neither completed the full treatment period. Importantly, no serious TEAEs occurred in either group.

This safety profile is consistent with what has been seen in other studies of dupilumab for EoE and other conditions. While side effects are possible, the drug is generally considered well-tolerated.

What This Means for Patients: Practical Takeaways

If you or a loved one has EoE, these findings offer several important messages:

• Treatment options are expanding. For years, the mainstays of EoE treatment were proton pump inhibitors (like omeprazole), topical steroids (like swallowed fluticasone), and dietary elimination. Dupilumab now provides another option, particularly for those who don’t respond well to other treatments.
• Early treatment may matter. Because dupilumab appears to help reverse some of the scarring and narrowing of the esophagus, there may be a benefit to using it earlier in the disease course, rather than as a last resort. Dr. Malamood noted that this finding “may shift it from a ‘treatment of last resort’ after failing proton pump inhibitors and/or topical steroids to a more first-line consideration—particularly in patients with evidence of remodeling at the time of diagnosis.”
• Monitoring is key. If you are on dupilumab, your doctor may use tools like EndoFLIP to monitor not just your symptoms and inflammation, but also the physical health of your esophagus. This could help guide treatment decisions over time.
• Long-term data are still needed. While these 24-week results are promising, the researchers are continuing to follow patients to see how dupilumab affects scarring and narrowing over a longer period. Dr. Dellon noted that “future data from this study will allow us to learn the longer-term impact of dupilumab on scarring and narrowing of the esophagus in EoE.”

Looking Ahead: The Future of EoE Treatment

The REMODEL trial represents an important step forward in understanding how to treat eosinophilic esophagitis. For decades, the focus was largely on managing symptoms and reducing inflammation. Now, there is evidence that we may be able to actually reverse some of the structural damage that EoE causes.

This is particularly important because esophageal remodeling—the scarring and narrowing that occurs over time—has been difficult to treat. Patients often require repeated dilation procedures to keep their esophagus open enough to swallow food. If medication alone can prevent or reverse this process, it could dramatically improve quality of life for many people.

However, it’s important to remember that this is one study with a relatively small number of participants. Larger studies over longer periods will be needed to confirm these findings and to determine which patients are most likely to benefit. Additionally, cost and insurance coverage remain significant barriers for many patients, as dupilumab is an expensive biologic medication.

If you have EoE and are interested in whether dupilumab might be right for you, talk to your gastroenterologist. They can help you weigh the potential benefits and risks based on your individual situation, including the severity of your disease, your response to other treatments, and your personal health goals.

In the meantime, these results offer genuine hope that we are moving closer to treatments that don’t just manage EoE—they may actually help heal the damage it causes.

Source: MedPage Today